188 related articles for article (PubMed ID: 14504104)
1. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
Cathcart K; Pinilla-Ibarz J; Korontsvit T; Schwartz J; Zakhaleva V; Papadopoulos EB; Scheinberg DA
Blood; 2004 Feb; 103(3):1037-42. PubMed ID: 14504104
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
3. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Jain N; Reuben JM; Kantarjian H; Li C; Gao H; Lee BN; Cohen EN; Ebarb T; Scheinberg DA; Cortes J
Cancer; 2009 Sep; 115(17):3924-34. PubMed ID: 19536894
[TBL] [Abstract][Full Text] [Related]
4. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
5. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
6. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Bocchia M; Gentili S; Abruzzese E; Fanelli A; Iuliano F; Tabilio A; Amabile M; Forconi F; Gozzetti A; Raspadori D; Amadori S; Lauria F
Lancet; 2005 Feb 19-25; 365(9460):657-62. PubMed ID: 15721470
[TBL] [Abstract][Full Text] [Related]
7. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
Oka T; Sastry KJ; Nehete P; Schapiro SJ; Guo JQ; Talpaz M; Arlinghaus RB
Leukemia; 1998 Feb; 12(2):155-63. PubMed ID: 9519777
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.
Rojas JM; Knight K; Wang L; Clark RE
Leukemia; 2007 Nov; 21(11):2287-95. PubMed ID: 17637811
[TBL] [Abstract][Full Text] [Related]
9. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
10. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
Li Z; Qiao Y; Liu B; Laska EJ; Chakravarthi P; Kulko JM; Bona RD; Fang M; Hegde U; Moyo V; Tannenbaum SH; Ménoret A; Gaffney J; Glynn L; Runowicz CD; Srivastava PK
Clin Cancer Res; 2005 Jun; 11(12):4460-8. PubMed ID: 15958631
[TBL] [Abstract][Full Text] [Related]
11. Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.
Bocchia M; Defina M; Aprile L; Ippoliti M; Crupi R; Rondoni M; Gozzetti A; Lauria F
Nat Rev Clin Oncol; 2010 Oct; 7(10):600-3. PubMed ID: 20808301
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
13. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell vaccination for patients with chronic myelogenous leukemia.
Takahashi T; Tanaka Y; Nieda M; Azuma T; Chiba S; Juji T; Shibata Y; Hirai H
Leuk Res; 2003 Sep; 27(9):795-802. PubMed ID: 12804637
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.
Clark RE; Christmas SE
Leuk Lymphoma; 2001; 42(5):871-80. PubMed ID: 11697642
[TBL] [Abstract][Full Text] [Related]
20. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
